Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Int J Obes (Lond). 2015 Jun 4;39(11):1607–1618. doi: 10.1038/ijo.2015.104

Figure 6. The effect of selective JAK1/JAK2 inhibition on SM inflammation and insulin sensitivity in HFD-fed mice.

Figure 6

Figure 6

Figure 6

Obese WT mice were administered a selective JAK1 and JAK2 inhibitor, baricitinib, in a dose of 10 mg/kg or vehicle control by oral gavage for 21 days. RNA was isolated from PMAT and “muscle” of baricitinib- and vehicle control–treated HFD-fed mice (n=8 mice/group). RT-PCR analysis of T cell markers in (A) “muscle” and (B) PMAT. Flow cytometry was performed to quantify the numbers of total CD3+, CD4+, and CD8+ T cells and CD11b+F4/80+ and CD11b+F4/80+CD11c+ M1 macrophages per gram tissue (n=5 mice/group) in (C) SM of vehicle control– and baricitinib-treated mice. (D) Intraperitoneal insulin tolerance test (1.5 U/kg) (n=5 mice/group). *P<0.05, **P<0.01. Two-way ANOVA was performed to compare the response to insulin in vehicle control– and baricitinib-treated mice.